Integra LifeSciences(IART) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - For the full year 2025, revenue was $1.635 billion, representing 1.5% growth on a reported basis and a 0.7% organic decline [15] - Fourth quarter revenues were $435 million, reflecting a decrease of 1.7% on a reported basis and an organic decline of 2.5% [17] - Full-year gross margin was 61.9%, down 260 basis points year-over-year, while adjusted EBITDA margin was 19.4%, down 60 basis points [16] - Adjusted EPS for the full year was $2.23, compared to $2.56 in 2024 [16] Business Line Data and Key Metrics Changes - Double-digit growth was achieved in Sterilink, Mayfield Capital, AURORA, DuraSorb, programmable valves, and fixed pressure valves for the full year 2025 [15] - Global neurosurgery delivered 1.4% organic growth, with strong performance in CereLink, MAYFIELD Capital, and AURORA [18] - Tissue Technologies revenues were $111.6 million, down 12.8% on both a reported and organic basis compared to the prior year [19] Market Data and Key Metrics Changes - International markets contributed to high single-digit growth in the CSF business, led by double-digit performance in China and Canada [18] - The capital business grew in the low double digits, benefiting from strong pipelines and disciplined commercial execution [18] Company Strategy and Development Direction - The company is focused on four strategic imperatives: delivering best-in-class quality, driving supply chain reliability, accelerating growth, and igniting innovation [10] - A new operating model has been implemented to reduce complexity and improve efficiency, alignment, and accountability [9] - The company aims to return key products to the market and recapture share while sharpening its approach to innovation and portfolio prioritization [26] Management's Comments on Operating Environment and Future Outlook - Management acknowledged uncertainty around new Section 122 tariffs but stated that 2026 guidance does not incorporate these changes [4] - The company expects improved cash flow in 2026, with operating cash flow projected to exceed $200 million [31] - Management remains confident in the long-term growth and value creation prospects, emphasizing the importance of quality management and supply reliability [14] Other Important Information - The company is actively monitoring the impact of recent tariff changes and has not accounted for any revenues from MediHoney in its 2026 guidance [50] - The Braintree manufacturing facility is expected to be operational by the end of June 2026, supporting the return of SurgiMend to the market in Q4 2026 [11] Q&A Session Summary Question: Free cash flow generation and improvement - Management explained that negative free cash flow was driven by timing of collections and restructuring costs, but expects significant improvement in 2026 [30] Question: Tissue Technologies business and CMS changes - Management noted that reimbursement changes are being monitored, and they do not expect negative impacts on their business due to pricing being within the new reimbursement range [32] Question: Growth assumptions for CSS and Tissue Tech - Management indicated that growth expectations for both CSS and Tissue Tech are below market due to supply constraints, not demand [40] Question: Status of MediHoney remediation efforts - Management confirmed that no revenues from MediHoney are accounted for in 2026 guidance, as remediation efforts continue [50] Question: Outlook for PriMatrix and DuraRepair - Management reported strong early reception for PriMatrix and DuraRepair following their relaunch, with plans for a measured ramp in 2026 [47]